Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. - Wikidata - wikimedia - TriplyDB

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.

http://www.wikidata.org/entity/Q44374816

about

The dopamine hypothesis of schizophrenia: version III--the final common pathway Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA Dopaminergic dysfunction in schizophrenia: salience attribution revisited.Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study.Dopamine receptors and Parkinson's disease Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study.The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia.PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.Review: The biological basis of antipsychotic response in schizophrenia.Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia.Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra.Constitutive hyperdopaminergia is functionally associated with reduced behavioral lateralization.Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats.Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia.Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis.Striatal dopamine synthesis capacity in twins discordant for schizophrenia The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study

P2860

Q22242827-F2FEB076-F7AF-4586-8944-0A046506B730 Q28484113-1B90FE68-81FA-45AE-A7DE-C09E8E39FE09 Q30475711-F470D5AA-297E-46F3-81FF-FA080077045C Q33707670-A33CBD56-6007-41E0-ACBC-7553A8D7A4AB Q33897463-1D9771EC-80E9-456E-8374-3D42CA2978A5 Q34250017-AC72FD3C-2116-4EB8-8C16-1DCCB481EF9D Q34392600-055C85ED-5E9E-4E99-9411-229B6CD56AD4 Q35545020-D89FB8F2-7244-41BC-8C56-716A448E1E1E Q37224949-D38F152C-33CD-48CA-B579-F26D28B83C9A Q37256211-83C428BD-3B57-491B-AFE3-AB98543AA188 Q37307572-3B9C87C4-61ED-4B14-8472-6F426A56DB9B Q37531716-67D35B45-A742-43FA-AC2F-BA8C7400D8A4 Q37606115-8B40D6F1-0EC4-4208-B415-14F1686C625A Q37638930-F5B0DEB0-1CDA-4457-AFD2-12AEC6561B2F Q37763856-1CA68D07-8E34-412F-B9AD-F31528B86811 Q38219577-2546E3F7-83E9-4743-A94D-BFB64211B733 Q41271272-2D670FA4-2A6E-434A-88DD-1B583BB19D95 Q42970777-C1327CD2-168C-4490-AD89-79EEBE4C3CA4 Q45049158-B9A061B6-7388-4557-B6A5-7C1C0E8A79C1 Q47325470-D57DFB7F-F265-4A76-9B2C-10CEB45C64D2 Q48219402-26D620ED-E1D4-4F15-9F87-160609DF570C Q50096180-6CE22034-BA79-4A3D-9213-1D48648C3E54 Q50192659-817D18F7-E4E6-41E4-AC88-D113C84EC972 Q57403286-E7FCC3D4-2D47-46D7-9AD1-162261834DB3 Q58793943-67A7D720-5DC3-494A-9B11-C12A474D88FA

P2860

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.

http://www.wikidata.org/entity/Q44374816

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@en

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@nl

type

label

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@en

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@nl

prefLabel

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@en

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@nl

P1433

Q44374816-6B8F3DF7-C1A4-45B5-893F-CD236F569F77

P1476

Q44374816-E7839787-CB69-4AC2-ACB6-0422084ACD87

P2093

Q44374816-2CDFC582-1FAB-40FC-BEB0-B568F3810BBD

Q44374816-2FF57EE6-D9C0-4E8F-A1DA-F9908F96FA8E

Q44374816-30632D1A-7B11-4CDE-92D8-EAA1038F07DE

Q44374816-395AB19F-5BC2-4FD4-AAFA-41C2A4ECFF02

Q44374816-455D2E47-7440-4C6F-B48C-EB055F091FF2

Q44374816-49762468-5D7B-47CF-A058-8D58118CB3EE

Q44374816-7205A738-2F0C-456C-ADD7-1E6C0197F03A

Q44374816-81CE44F6-F62A-44D7-8CFF-2F9DF9A19FB6

Q44374816-C6FA5024-E437-4216-8CC3-E17AACECE970

Q44374816-CB0BEC43-5329-471D-9A57-B98860559D7C

P2860

Q44374816-0243F946-CC42-441B-B125-13EB84092E3F

Q44374816-0E1A0CFA-C30E-4D09-817B-65E7AFD84F59

Q44374816-109D9850-2EB1-4930-831E-02754A7986B0

Q44374816-16324FF8-C42B-4B95-9DDB-AE60BB00E09A

Q44374816-1AB8512A-8CE8-47F1-A90F-FBB4D93CEA3E

Q44374816-208A6AF9-AE22-40A1-B808-976C9947C192

Q44374816-2370F1F2-773A-4BC9-ACB5-F620845C9F0E

Q44374816-2E05FFEB-04E7-4828-BB20-25666706243B

Q44374816-2F2EBB37-B6F3-4190-A6F9-B5660CF3F163

Q44374816-3E06C378-23EC-44B1-BCB4-D7ECF4257F88

P2888

Q44374816-E31D10D9-9E92-438D-98A5-317F16449657

P304

Q44374816-2BB3D29B-83BC-43D5-9E32-114BBEB88D9D

P31

Q44374816-61D2288D-6217-419A-9201-9D4AB4E3B8A1

P356

Q44374816-C5A2E08B-5CBC-4474-9FCB-C78DB9F17146

P407

Q44374816-E01EFC14-C956-4634-93E3-33CD2EEC67E3

P433

Q44374816-C5451CC3-D5C5-483E-A6E5-3E7D07B7E20C

P478

Q44374816-79FFF4F5-4111-4223-A02E-C8BF3B879E72

P50

Q44374816-2D7BC0AD-EB38-42EE-9154-766A19C5BB36

P577

Q44374816-8A5824F3-81BA-4E70-9F93-5B51FCA7F427

P6179

Q44374816-5D9D583D-4164-4CB0-9834-3370A3CDF4D8

P698

Q44374816-A397491A-E52D-4989-BD74-71D641D8D808

P921

Q44374816-22654f88-bc38-443f-b881-4c1a14c39793

Q44374816-57571235-EED2-4A13-9231-0EFEFFEEFBDE

P356

P1433

Neuropsychopharmacology

P1476

Subchronic haloperidol downreg ...... chizophrenic patients in vivo.

@en

P2093

Dean F Wong

http://www.w3.org/2001/XMLSchema#string

Eugen Davids

http://www.w3.org/2001/XMLSchema#string

Gerhard Gründer

http://www.w3.org/2001/XMLSchema#string

Hans-Georg Buchholz

http://www.w3.org/2001/XMLSchema#string

Ingo Vernaleken

http://www.w3.org/2001/XMLSchema#string

Matthias J Müller

http://www.w3.org/2001/XMLSchema#string

Nilufar Heydari

http://www.w3.org/2001/XMLSchema#string

Ole L Munk

http://www.w3.org/2001/XMLSchema#string

Paul Cumming

http://www.w3.org/2001/XMLSchema#string

Peter Bartenstein

http://www.w3.org/2001/XMLSchema#string

P2860

Homovanillic Acid Measurement in Clinical Research: A Review of Methodology

A rating scale for drug-induced akathisia

The positive and negative syndrome scale (PANSS) for schizophrenia

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

Increased dopamine transmission in schizophrenia: relationship to illness phases.

Neurotransmitter interactions in schizophrenia--therapeutic implications.

Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.

The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Elevated dopa decarboxylase activity in living brain of patients with psychosis.

P2888

P304

787-794

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300103

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013337906

http://www.w3.org/2001/XMLSchema#string

P698

12655326

http://www.w3.org/2001/XMLSchema#string

P921